Infants under the age of 12 months who are diagnosed with botulism are the primary recipients of BIG-IV. Since their immune systems are not fully developed, they are particularly vulnerable to the effects of the botulinum toxin. Early administration of BIG-IV can significantly reduce the severity and duration of illness.
